Table 1 Baseline characteristics and mortality before and after matching in SPH1
Variable | Norepinephrine | Vasopressin | p |
|---|---|---|---|
Baseline characteristics before matching of norepinephrine- vs. vasopressin-treated patients in SPH1 | |||
Age (years), X ± SD | 60.7 ± 16.2 | 56.1 ± 15.7 | < 0.001 |
APACHE II, X ± SD | 25.6 ± 8.0 | 28.8 ± 8.9 | < 0.001 |
Gender (% male) | 61.8 | 73.3 | 0.007 |
Surgical (%) | 39.2 | 35.2 | 0.146 |
Respiratory (%) | 88.3 | 92.1 | 0.17 |
Renal (%) | 68.1 | 81.2 | < 0.001 |
Coagulation (%) | 23.3 | 36.4 | < 0.001 |
Hepatic (%) | 14.3 | 22.4 | 0.013 |
Neurological (%) | 64.7 | 79.4 | < 0.001 |
Ventilated (%) | 92.7 | 89.1 | 0.142 |
Any chronic disease (%) | 44.8 | 55.8 | 0.013 |
Norepinephrine dose (ug/min) | 13.2 ± 14.8 | 21.4 ± 21.7 | < 0.001 |
Baseline characteristics after matching of norepinephrine- vs. vasopressin-treated patients in SPH1 | |||
Age (years), X ± SD | 57.1 ± 15.1 | 56.4 ± 15.4 | 0.65 |
APACHE II, X ± SD | 28.1 ± 8.3 | 28.4 ± 8.4 | 0.782 |
Gender (% male) | 67.1 | 72.8 | 0.27 |
Surgical (%) | 34.8 | 34.8 | 1 |
Respiratory (%) | 93.0 | 91.8 | 0.671 |
Renal (%) | 74.7 | 81.0 | 0.176 |
Coagulation (%) | 28.5 | 36.1 | 0.149 |
Hepatic (%) | 18.4 | 22.2 | 0.401 |
Neurological (%) | 69.0 | 78.5 | 0.055 |
Ventilated (%) | 94.3 | 89.2 | 0.101 |
Any chronic disease (%) | 51.9 | 54.4 | 0.652 |
Norepinephrine dose (ug/min) | 15.9 ± 16.7 | 19.8 ± 18.9 | 0.139 |
Mortality of norepinephrine- vs. vasopressin-treated patients in SPH1 | |||
28-day mortality (%) | 46.2 | 60.8 | 0.009 |